Source: SourceOECD Social Issues/Migration/Health, Volume 2009, Number 21, November 2009 , pp. 113-121(9)
Abstract:While research in pharmacogenetics is proceeding rapidly, at the start of 2009 there were only just over a dozen pharmacogeneticsbased products on the market. A number of scientific, economic and regulatory challenges need to be overcome if pharmacogenetics is to be taken up more widely within health‐care systems. It is not yet clear to the private sector what business models will deliver acceptable returns on investment. In the public sector, governments have a number of levers which they could use to create an "enabling" environment for pharmacogenetics, while continuing to provide the necessary checks and balances.
Document Type: Review Article
Publication date: November 1, 2009